FDA Approves Arrowhead Pharma’s Redempo for Rare Genetic Disease
A groundbreaking new treatment for familial chylomicronemia syndrome (FCS) has received approval from the Food and Drug Administration, offering hope to patients suffering from this severe and often debilitating genetic condition.
Arrowhead Pharmaceuticals announced on Tuesday that its novel therapy, redempo, has been cleared to reduce dangerously high triglyceride levels in adults diagnosed with FCS. The approval marks a significant advancement in the treatment of this rare disorder, which impacts the body’s ability to process fats.
Familial chylomicronemia syndrome is characterized by extremely elevated triglyceride levels, stemming from a genetic defect. According to Arrowhead, this can lead to a cascade of serious health complications, including acute and potentially fatal pancreatitis, chronic abdominal pain, the development of diabetes, hepatic steatosis (fatty liver disease), and even cognitive impairment.
“This approval represents a major step forward for patients who have limited treatment options,” a company release stated.
The active ingredient in redempo, plozasiran, is a first-in-class therapy that works by targeting the underlying cause of the disease. Beyond FCS, Arrowhead is currently evaluating plozasiran in clinical trials for its potential to lower triglycerides in individuals with severe hypertriglyceridemia and dyslipidemia – broader conditions involving abnormal lipid levels. The company, based in Pasadena, California, anticipates further data on these applications in the coming months.
The FDA’s decision provides a much-needed therapeutic option for a small but critically ill patient population. While the exact prevalence of FCS is unknown, it is considered a rare disease, making the development of targeted treatments particularly challenging.
For more information, contact Kelly Cloonan at [email protected].
(END) Dow Jones Newswires
November 18, 2025 12:23 ET (17:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
